TissGeneSummary for APOA2 |
Gene summary |
Basic gene information | Gene symbol | APOA2 |
Gene name | apolipoprotein A-II | |
Synonyms | Apo-AII|ApoA-II|apoAII | |
Cytomap | UCSC genome browser: 1q23.3 | |
Type of gene | protein-coding | |
RefGenes | NM_001643.1, | |
Description | apolipoprotein A2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 107670 | |
HGNC : HGNC | ||
Ensembl : ENSG00000158874 | ||
HPRD : 00129 | ||
Vega : OTTHUMG00000034346 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_APOA2 | |
BioGPS: 336 | ||
Pathway | NCI Pathway Interaction Database: APOA2 | |
KEGG: APOA2 | ||
REACTOME: APOA2 | ||
Pathway Commons: APOA2 | ||
Context | iHOP: APOA2 | |
ligand binding site mutation search in PubMed: APOA2 | ||
UCL Cancer Institute: APOA2 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Liver | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LIHC | |
Reference showing the relevant tissue of APOA2 | ||
Description by TissGene annotations | Cancer gene TissgsKTS CNV gained TissGeneKTS |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID | GO:0002740 | negative regulation of cytokine secretion involved in immune response | 12458630 | GO:0006457 | protein folding | 14967812 | GO:0006656 | phosphatidylcholine biosynthetic process | 14967812 | GO:0009395 | phospholipid catabolic process | 14967812 | GO:0009749 | response to glucose | 14988251 | GO:0010873 | positive regulation of cholesterol esterification | 14967812 | GO:0010903 | negative regulation of very-low-density lipoprotein particle remodeling | 14967812 | GO:0018158 | protein oxidation | 12576517 | GO:0018206 | peptidyl-methionine modification | 12576517 | GO:0031647 | regulation of protein stability | 14967812 | GO:0033344 | cholesterol efflux | 11162594 | GO:0033700 | phospholipid efflux | 11162594 | GO:0034370 | triglyceride-rich lipoprotein particle remodeling | 14967812 | GO:0034374 | low-density lipoprotein particle remodeling | 8106353 | GO:0034375 | high-density lipoprotein particle remodeling | 14967812 | GO:0034380 | high-density lipoprotein particle assembly | 218942 | GO:0034384 | high-density lipoprotein particle clearance | 10764676 | GO:0042632 | cholesterol homeostasis | 14967812 | GO:0043085 | positive regulation of catalytic activity | 14967812 | GO:0043691 | reverse cholesterol transport | 14967812 | GO:0045416 | positive regulation of interleukin-8 biosynthetic process | 11591715 | GO:0046340 | diacylglycerol catabolic process | 14967812 | GO:0050995 | negative regulation of lipid catabolic process | 14967812 | GO:0050996 | positive regulation of lipid catabolic process | 8640403 | GO:0060192 | negative regulation of lipase activity | 14967812 | GO:0060621 | negative regulation of cholesterol import | 10764676 | GO:0060695 | negative regulation of cholesterol transporter activity | 8106353 | GO:0002740 | negative regulation of cytokine secretion involved in immune response | 12458630 | GO:0006457 | protein folding | 14967812 | GO:0006656 | phosphatidylcholine biosynthetic process | 14967812 | GO:0009395 | phospholipid catabolic process | 14967812 | GO:0009749 | response to glucose | 14988251 | GO:0010873 | positive regulation of cholesterol esterification | 14967812 | GO:0010903 | negative regulation of very-low-density lipoprotein particle remodeling | 14967812 | GO:0018158 | protein oxidation | 12576517 | GO:0018206 | peptidyl-methionine modification | 12576517 | GO:0031647 | regulation of protein stability | 14967812 | GO:0033344 | cholesterol efflux | 11162594 | GO:0033700 | phospholipid efflux | 11162594 | GO:0034370 | triglyceride-rich lipoprotein particle remodeling | 14967812 | GO:0034374 | low-density lipoprotein particle remodeling | 8106353 | GO:0034375 | high-density lipoprotein particle remodeling | 14967812 | GO:0034380 | high-density lipoprotein particle assembly | 218942 | GO:0034384 | high-density lipoprotein particle clearance | 10764676 | GO:0042632 | cholesterol homeostasis | 14967812 | GO:0043085 | positive regulation of catalytic activity | 14967812 | GO:0043691 | reverse cholesterol transport | 14967812 | GO:0045416 | positive regulation of interleukin-8 biosynthetic process | 11591715 | GO:0046340 | diacylglycerol catabolic process | 14967812 | GO:0050995 | negative regulation of lipid catabolic process | 14967812 | GO:0050996 | positive regulation of lipid catabolic process | 8640403 | GO:0060192 | negative regulation of lipase activity | 14967812 | GO:0060621 | negative regulation of cholesterol import | 10764676 | GO:0060695 | negative regulation of cholesterol transporter activity | 8106353 |
Top |
TissGeneExp for APOA2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
STAD | -0.473805575 | -1.803280575 | 1.329475 | 0.00937 | 0.032722252 |
COAD | -1.203432499 | -2.246255576 | 1.042823077 | 0.0138 | 0.029241586 |
KIRP | -1.920505575 | -0.893793075 | -1.0267125 | 0.000193 | 0.00061639 |
Top |
TissGene-miRNA for APOA2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for APOA2 |
TissGeneSNV for APOA2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.R55W | BLCA | 1 |
p.M49I | SKCM | 1 |
p.M34V | BLCA | 1 |
p.M1I | TGCT | 1 |
p.A98D | UCEC | 1 |
p.E93K | BLCA | 1 |
p.M1V | BLCA | 1 |
p.K69N | UCEC | 1 |
p.G80* | LUSC | 1 |
Top |
TissGeneCNV for APOA2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for APOA2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | ChiTaRs | NA | AI064980 | DEFA1-APOA2 | chr8:6856718 | chr1:161192236 | |
Chimerdb3.0 | ChiTaRs | NA | AF063569 | APOA2-PFKFB2 | chr1:161192731 | chr1:207221981 | |
Chimerdb3.0 | ChiTaRs | NA | AI207725 | APOA2-SND1 | chr1:161193414 | chr7:127732510 | |
Chimerdb3.0 | ChiTaRs | NA | AI336287 | FHL3-APOA2 | chr1:38462846 | chr1:161192762 | |
Chimerdb3.0 | ChiTaRs | NA | AI064779 | APOA2-PNP | chr1:161193418 | chr14:20944930 | |
Chimerdb3.0 | ChiTaRs | NA | AF090896 | APOA2-PFKFB2 | chr1:161192731 | chr1:207219676 | |
Chimerdb3.0 | FusionScan | PRAD | TCGA-EJ-5518-01A | MEF2D-APOA2 | 5'UTR-5'UTR | chr1:156470277 | chr1:161193215 |
Chimerdb3.0 | TopHat-Fusion | PRAD | TCGA-EJ-5518-01A | MEF2D-APOA2 | 5'UTR-5'UTR | chr1:156470277 | chr1:161193214 |
Top |
TissGeneNet for APOA2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for APOA2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for APOA2 |
TissGeneDrug for APOA2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for APOA2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0004153 | Atherosclerosis | 12 | BeFree,GAD |
umls:C0003850 | Arteriosclerosis | 11 | BeFree |
umls:C0028754 | Obesity | 7 | BeFree,GAD |
umls:C0010068 | Coronary heart disease | 6 | BeFree,GAD |
umls:C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 6 | BeFree,GAD |
umls:C0010054 | Coronary Arteriosclerosis | 5 | BeFree |
umls:C0020474 | Hyperlipidemia, Familial Combined | 5 | BeFree,LHGDN |
umls:C0002726 | Amyloidosis | 4 | BeFree |
umls:C1956346 | Coronary Artery Disease | 4 | BeFree,LHGDN |
umls:C0019196 | Hepatitis C | 3 | BeFree,GAD |
umls:C2712907 | Combined hyperlipidemia | 3 | BeFree |
umls:C0020459 | Hyperinsulinism | 2 | BeFree |
umls:C0020473 | Hyperlipidemia | 2 | BeFree,GAD |
umls:C0020557 | Hypertriglyceridemia | 2 | GAD,LHGDN |
umls:C0039292 | Tangier Disease | 2 | BeFree |
umls:C0518010 | body mass | 2 | GAD |
umls:C2239176 | Liver carcinoma | 2 | BeFree |
umls:C0005684 | Malignant neoplasm of urinary bladder | 1 | GAD |
umls:C0007959 | Charcot-Marie-Tooth Disease | 1 | BeFree |
umls:C0011847 | Diabetes | 1 | BeFree |
umls:C0011849 | Diabetes Mellitus | 1 | BeFree |
umls:C0019158 | Hepatitis | 1 | BeFree |
umls:C0019159 | Hepatitis A | 1 | BeFree |
umls:C0020445 | Hypercholesterolemia, Familial | 1 | BeFree,CLINVAR,CTD_human |
umls:C0020456 | Hyperglycemia | 1 | BeFree |
umls:C0020550 | Hyperthyroidism | 1 | RGD |
umls:C0021368 | Inflammation | 1 | GAD |
umls:C0021655 | Insulin Resistance | 1 | GAD |
umls:C0023195 | Lecithin Acyltransferase Deficiency | 1 | BeFree |
umls:C0024117 | Chronic Obstructive Airway Disease | 1 | GAD |
umls:C0024305 | Lymphoma, Non-Hodgkin | 1 | GAD |
umls:C0027051 | Myocardial Infarction | 1 | BeFree |
umls:C0030481 | Tropical Spastic Paraparesis | 1 | BeFree |
umls:C0042721 | Viral hepatitis | 1 | BeFree |
umls:C0154251 | Lipid Metabolism Disorders | 1 | BeFree |
umls:C0156344 | Endometriosis of ovary | 1 | BeFree |
umls:C0242379 | Malignant neoplasm of lung | 1 | GAD |
umls:C0268382 | Amyloid nephropathy | 1 | BeFree |
umls:C0342883 | Cholesteryl Ester Transfer Protein Deficiency | 1 | BeFree |
umls:C0342895 | Fish-Eye Disease | 1 | BeFree |
umls:C0442874 | Neuropathy | 1 | BeFree |
umls:C0524620 | Metabolic Syndrome X | 1 | BeFree |
umls:C1261473 | Sarcoma | 1 | BeFree |
umls:C1271104 | Blood pressure finding | 1 | GAD |
umls:C1272641 | Systemic arterial pressure | 1 | GAD |
umls:C1522137 | Hypertriglyceridemia result | 1 | GAD |
umls:C1559271 | Non-Malignant Ascites Adverse Event | 1 | BeFree |
umls:C2936179 | Obesity, Visceral | 1 | BeFree |
umls:C3714619 | Insulin resistance syndrome | 1 | BeFree |
umls:C0745103 | Hyperlipoproteinemia Type IIa | 0 | CTD_human |